期刊文献+

行TACE治疗后原发性肝细胞癌患者预后的影响因素 被引量:4

Prognostic Factors of Patients with Primary Hepatocellular Carcinoma Treated with TACE
下载PDF
导出
摘要 目的探讨行TACE术后的原发性肝细胞癌患者预后的影响因素。方法回顾性分析2006年3月至2009年10月于云南省肿瘤医院介入医学科就诊的108例原发性肝细胞癌(HCC)患者临床资料,通过建立Cox回归模型,探究各因素对行TACE治疗的HCC患者预后的影响。结果 Cox回归模型显示,TACE次数对HCC患者的生存情况影响的P值为0.007<0.05,具有统计学差异,行多次TACE术者的生存风险为行单次TACE术者的0.465倍;癌灶分布于肝左右叶P值为0.016,生存风险较单分布于肝左或肝右叶高;NLR>3.97者P值约为0.05。结论 TACE次数、癌灶分布情况、NLR对行TACE治疗HCC患者的生存情况有显著影响。 Objective To investigate the prognostic factors of primary hepatocellular carcinoma(HCC after TACE1. Methods The clinical data of 108 patients with primary hepatocellular carcinoma(HCC) from March 2006 to October 2009 in the Department of Interventional Medicine of Yunnan Cancer Hospital were analyzed retrospectively. The Cox regression model was established to explore the influence of various factors on the prognosis of HCC patients treated with TACE. Results The Cox regression model showed that the number of TACE had a significant effect on the survival of HCC patients(P<0.05), and the survival risk of the patients undergoing multiple TACE operations was significantly lower than that of the control group. P value of whose cancer located in the whole liver was 0.016, and the survival risk was higher than those distributed only in one liver lobe. P value of NLR>3.97 was 0.050. Conclusion The number of TACE and the distribution of cancer foci have significant effect on the survival of HCC patients treated with TACE.
作者 谭骅 仁虹 赵玲 游顶云 杨亚琛 TAN Hua;REN Hong;ZHAO Ling;YOU Ding-yun;YANG Ya-chen(Department of Intervention,The 3rd Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital,Kunming Yunnan 650118;Clinical Innovation Class 2016,Basic Medical College,Kunming Medical University, Kunming Yunnan 650500,China;Science and Technology Department,Kunming Medical University, Kunming Yunnan 650500,China)
出处 《昆明医科大学学报》 CAS 2019年第3期29-34,共6页 Journal of Kunming Medical University
基金 国家自然科学基金资助项目(81660545)
关键词 肝细胞癌 TACE治疗 预后 COX回归模型 Hepatocellular carcinoma TACE Prognosis Cox regression model
  • 相关文献

参考文献5

二级参考文献36

  • 1吴孟超.肝癌外科综合治疗的现状和前景[J].中华肝胆外科杂志,2006,12(1):1-4. 被引量:58
  • 2Soroup DF,Berlin JA,Morton SC,et al.Meta-analysis of observational Sutdies in Epidemiology:A PorPosal for Reporting[J].JAMA,2000,283(15):2008-2012.
  • 3Hailey D,ohinmaa A,Roine R.Sutdy quality and evidence of benefit in recent assessments of telemedicine[J].J Telemed Telecare,2004,10(6):318-324.
  • 4Aldesron P,Green S,Higgin JPT,editors.Cochrane Reviewers Handbook 4.2.2[updated December2003].in:The Cochrane Library,Iss1,2004.Chiehester.UK:John Wiley&Sons,Ltd.
  • 5Kjacrgard LL,Villumsen J,Gluud C.Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses[J].Ann inten Med,2001,135(11):982-989.
  • 6Wu CC,Ho YZ,Ho WL,et al.Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma:a reappraisal[J].Br J Surg,1995,82 (1):122-126.
  • 7Yamasaki S,Hasegawa H,Kinoshita H,et al.A prospective randomized trial of preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma[J].Jpn J Cancer Res,1996,87(2):206-211.
  • 8Gerunda GE,Neri D,Merenda R,et al.Role of Transarterial Chemoembolization Before Liver Resection for Hepatocarcinoma[J].Liver Transpl,2000,6(5):619-626.
  • 9Zhou WP,Lai EC,Li AJ,et al.A prospective,randomized,controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J].Ann Surg,2009,249(2):195-202.
  • 10Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.

共引文献61

同被引文献33

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部